Insulin resistance in rheumatoid arthritis: The impact of the anti-TNF-α therapy: Annals of the New York Academy of Sciences

Annals of the New York Academy of Sciences

Volumn 1193, Issue , 2010, Pages 153-159

  Gonzalez Gay, Miguel A ^a   Gonzalez Juanatey, Carlos ^a   Vazquez Rodriguez, Tomas R ^a   Miranda Filloy, Jose A ^a   Llorca, Javier ^b,c  

^a HOSPITAL XERAL CALDE   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Anti TNF therapy; Inflammation; Insulin resistance; Rheumatoid arthritis; TNF

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOSE; INFLIXIMAB; INSULIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ATHEROGENESIS; BODY MASS; CONFERENCE PAPER; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; PREVALENCE; RHEUMATOID ARTHRITIS;

EID: 77951227180     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05287.x     Document Type: Conference Paper

References (37)

1. Grundy, S.M., H.B. Brewer, Jr., J.I. Cleeman, et al. 2004. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart AssociationConference on scientific issues related to definition. Circulation 109: 433-438.
2. Eckel, R.H., S.M. Grundy & P.Z. Zimmet. 2005. The metabolic syndrome. Lancet 365: 1415-1428.
3. Grundy, S.M., J.I. Cleeman, S.R. Daniels, et al. 2005. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112: 2735-2752.
4. Grundy, S.M. 2007. Controversy in clinical endocrinology. Metabolic syndrome: amultiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92: 399-404.
5. Bray,G.A. 2004.Medical consequences of obesity. J. Clin. Endocrinol. Metab. 89: 2583-2589.
6. Hanley, A.J., K. Williams, M.P. Stern & S.M. Haffner. 2002. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 25: 1177-1184.
7. Reilly, M.P., M.I. Wolfe, T. Rhodes, et al. 2004. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110: 803-809.
8. Chung, C.P., A. Oeser, J.F. Solus, et al. 2008. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196: 756-763.
9. Fukuzawa, M., J. Satoh, X. Qiang, et al. 1999. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Diabetes Res. Clin. Pract. 43: 147-154.
10. Hotamisligil, G.S., P. Peraldi, A. Budavari, et al. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 27: 665-668.
11. Dessein, P.H., B.I. Joffe, A. Stanwix, et al. 2002. The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis. J. Rheumatol. 29: 462-466.
12. Gonzalez-Gay, M.A., C. Gonzalez-Juanatey & J. Martin. 2005. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin. Arthritis Rheum. 35: 8-17.
13. Sattar,N.,D.W.McCarey, I.I.Capell&I.B.McInnes, et al. 2003. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
14. Gonzalez-Gay, M.A., C. Gonzalez-Juanatey & J. Martin. 2006. Inflammation and endothelial dysfunction in rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 115-117.
15. Dessein, P.H., A. Stanwix & B.I. Joffe. 2002. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 4: R5.
16. Dessein, P.H., B.I. Joffe & A. Stanwix. 2002. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res. 4: R12.
17. Chung,C., A.Oeser, J.F. Solus, et al. 2008. Inflammationassociated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 58: 2105-2112.
18. Dessein,P.H.&B.I. Joffe. 2006. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 54: 2765-2775.
19. Pasceri, V. & E.T. Yeh. 1999. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100: 2124-2126.
20. Lipsky, P.E., D.M. van der Heijde, E.W. St. Clair, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
21. Avouac, J. & Y. Allanore. 2008. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin. Pharmacother. 9: 1121-1128.
22. Hürlimann, D., A. Forster, G. Noll, et al. 2002. Antitumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: 2184-21287.
23. Gonzalez-Juanatey, C., J. Llorea, A. Sanchez-Andrade, et al. 2006. Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin. Exp. Rheumatol. 24: 309-1212
24. Gonzalez-Juanatey, C., A. Testa, A. Garcia-Castelo, et al. 2004. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 51: 447-450.
25. Gonzalez-Gay, M.A., M.T. Garcia-Unzueta, J.M. DeMatias, et al. 2006. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 373-379.
26. Bonora, E., S. Kiechl, J.Willeit, et al. 1998. Prevalence of insulin resistance in metabolic disorders. Bruneck Study Diabetes 47: 1643-1649.
27. Katz, A., S.S. Nambi, K. Mather, et al. 2000. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85: 2402-2410.
28. Reilly, M.P., M.L. Wolfe, T. Rhodes, et al. 2004. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110: 803-809.
29. Imperato, A.K., C.O. Bingham III & S.B. Abramson. 2004. Overview of benefit/risk of biological agents. Clin. Exp. Rheumatol. 22(5 Suppl 35): S108-S114.
30. Gonzalez-Gay, M.A., J.M. DeMatias, C. Gonzalez-Juanatey, et al. 2006. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 83-86.
31. Van Gestel, A.M. & G. Stucki. 1999. Evaluation of established rheumatoid arthritis. Baillieres Best. Pract. Res. Clin. Rheumatol. 13: 629-644.
32. Kiortsis, D.N., A.K. Mavridis, S. Vasakos, et al. 2005. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann. Rheum. Dis. 64: 765-766.
33. Seriolo, B., S. Paolino, C. Ferrone & M. Cutolo. 2008. Impact of long-term anti-TNF-treatment on insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 26: 159-160.
34. Tan L.S., S. Tomlinson, B. Chu, et al. 2007. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26: 1495-1498.
35. Huvers F.C., C. Popa, M.G. Netea, et al. 2007. Improved insulin sensitivity by anti-TNF-antibody treatment in patients with rheumatic diseases. Ann. Rheum. Dis. 66: 558-559.
36. Seriolo, B., C. Ferrone & M. Cutolo. 2008. Longterm anti-tumor necrosis factor-treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J. Rheumatol. 35: 355-357.
37. Rosenvinge, A., R. Krogh-Madsen, B. Baslund & B.K. Pedersen. 2007. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand. J. Rheumatol. 36: 91-96.